Parkland

Board of Managers

Agenda for the ***Board of Managers*** meeting of the Dallas County Hospital District is scheduled for ***Wednesday, March 27, 2024, at 12:50 PM (or immediately following HOMES meeting)*** at 5200 Harry Hines Blvd (WISH Building) Dallas, TX 75235, Conference Room 02-175. (If assistance is needed in locating the room, please see the Administration receptionist on the 4th floor, 04-131.) A quorum will be physically present at the location of the meeting. Videoconferencing access is also possible via Webex. That application is available at https://www.webex.com/downloads.html. Teleconferencing access is possible by calling +1-415-655-0001. Both virtual access forms require inputting (meeting number: 2633 771 9241; meeting password: 1234) to join the meeting. The ***Board of Managers*** reserves the right to exercise discretion and may convene in Executive Session as permitted by Texas Government Code §§551.071 (consultation with attorney), 551.072 (deliberations regarding real estate), 551.074 (personnel matters), 551.076 (deliberations regarding security devices or security audits), 551.078 and/or 551.0785 (deliberations by medical committee or by governmental body that administers a public insurance, health or retirement plan regarding individuals' medical or psychiatric records), 551.085 (deliberation by governing board of certain providers of health care services), 551.087 (deliberation regarding economic development negotiations), 551.088 (deliberation regarding test item); Texas Government Code §418.183 (deliberation of information under §§418.175 – 418.182 for purposes of disaster management or disaster planning); Texas Health & Safety Code §161.032 (medical committee or medical peer review committee records, information or reports; and/or medical committee or medical peer review committee proceedings under Tex. Health & Safety Code Chapter 161 and/or Tex. Occ. Code Chapters 151 and 160); and/or as otherwise authorized by law on any item listed below. The ***Board of Managers*** may consider any of the agenda items in open or executive session and may continue the meeting as necessary to accomplish the business at the time and place designated by the Chair to reconvene.

	PAGE	TIME (MIN)	PRESENTER(S)
I. Opening/Call to Order/Declare a Quorum Present/Mission Statement/Opening Remarks ***Advance Wellness | Relieve Suffering | Develop and Educate*** **I CARE** **I**ntegrity **C**ompassion and Collaboration **A**ccountability **R**espect **E**quity			Chair
A. Invocation by Pastor Law	*4*	5	Pastor Law, Senior Pastor Northway Church
B. Public Comments Regarding Agenda Items *See public comment registration information and rules at https://www.parklandhospital.com/board-of-managers*			
C. Public Comments Regarding Non-Agenda Items *See public comment registration information and rules at https://www.parklandhospital.com/board-of-managers*			
II. Consent Agenda			
A. Minutes 2024-02-07 Talent Development and Executive Compensation Committee	*5*	1	Chair
B. Minutes 2024-02-07 Governance, Compliance and Ethics Committee	*9*		
C. Minutes 2024-02-27 Budget & Finance Committee	*13*		
D. Minutes 2024-02-28 Quality of Care & Patient Safety Committee	*20*		
E. Minutes 2024-02-28 Board of Managers	*25*		

	PAGE	TIME (MIN)	PRESENTER(S)
F. Approve Parkland Center for Clinical Innovation (PCCI) Board Re-appointments	*30*		
G. Approve Contracts over $200,000	*34*		
H. Approve Capital Substitution(s)	*81*		
I. Approve Patient Settlements	*84*		
J. Approve Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers	*85*		
III. Reports Requiring Deliberation(s) or Approval(s)			
A. CEO System Update	*87*	20	Fred Cerise, MD
B. Questions & Discussion Related to CEO System Update	*88*	10	Chair
C. Parkland Health Foundation Update	*89*	20	Michael Horne, EdD
D. Questions & Discussion Regarding Parkland Health Foundation Update	*102*	10	Chair
E. Artificial Intelligence (AI) Update	*103*	40	Joe Longo
F. Questions & Discussion Regarding Artificial Intelligence (AI) Update	*104*	20	Chair
G. Discuss Board of Managers Annual Operating Plan Meeting and Board Development	*105*	5	Chair
IV. Executive Session Tex. Gov't Code §§551.072, 551.074			
A. Real Estate Purchase Opportunity	*106*	10	Fred Cerise, MD
B. Questions & Discussion Regarding Real Estate Purchase Opportunity	*107*	10	Chair
C. Discussion Regarding Roles and Responsibilities of the Board of Managers in the Governance and Strategic Direction of the System	*108*	30	Chair
D. Personnel Matters Pertaining to Duties and Responsibilities of Chief Executive Officer	*109*	15	Chair
E. Personnel Matters Pertaining to Duties and Responsibilities of Board Members	*110*	15	Chair
V. Executive Session Reference Documents Tex. Occup. Code §160.007 Tex. Health & Safety Code §§161.0315 & 161.032 Tex. Gov't Code §§551.071			
A. Medical Executive Committee Credentialing Report	*111*		
B. Delineation of Privileges Cardiovascular Disease – Laser Privileges	*150*		
C. Delineation of Privileges Non-Physician Clinical Provider Staff – Pediatrics/Neonatology	*171*		

	PAGE	TIME (MIN)	PRESENTER(S)
D. Patient Settlements		183	
VI. Action Items			
A. Board May Take Action on Any Agenda Item(s) Above			Chair
VII. Adjourn			Chair
A. Closing Remarks			
B. Call to Adjourn			

Invocation

Minutes 2024-02-07 Talent Development and Executive Compensation Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Minutes of the Talent Development and Executive Compensation Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, February 7, 2024, scheduled for 12:00 p.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via Webex. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Lisa Sutter noted a quorum was physically present and called the meeting to order at 12:08 p.m. Committee members Reina Gonzalez, JD; Vincent Hall; and Elizabeth Palacios, MD, were present.

Committee member Farida Minner, RN was not present.

Board Member attendees included:.

Staff Present (via Webex and in-person) included:

DeLancey Johnson, SVP & Associate Chief Talent Officer
Donna Richardson, EVP Chief Nursing Executive
Edmundo Castañeda, EVP & Chief Operating Officer
Felicia Miller, EVP & Chief Talent Officer
Forrest Stovall, Governance Program Manager
Fred Cerise, President & Chief Executive Officer
Jessica Hernandez, SVP Chief DEI Officer
Kellee Boardingham, Executive Assistant
Lauryn Minter, Director Workforce Equity
Melanie Roberts, SVP Chief Compliance and Ethics Officer
Rick Humphrey, EVP & Chief Financial Officer
Roberto de la Cruz, EVP Chief Clinical Officer (Webex)
Saul Cordero, SVP Chief Governance & Strategy Officer (Webex)
Sharon Chisholm, Administrative Director OTM
Stephanie Speights, SVP Talent Mgmt Development
Steven Roth, EVP & Chief Legal Officer
Vic Summers, SVP Internal Audit

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Office of Talent Management Overview

Felicia Miller provided an update from Q4 2023, highlighted Q1 2024 goals and Parkland's commitment to making a positive impact on employee staff.

The Committee members asked questions and received additional information related to the Office of Talent Management Overview.

B. Benefits Update

Dr. DeLancey Johnson provide the Benefits Update. He reported the Retirement Benefits Program Transition went off with no hiccups. Next, he provided key updates on Cigna Go-Live and Pharmacy Plan.

The Committee members asked questions and received additional information specifically related to the Employee Assistance Program.

C. Workforce Planning & Development

Stephanie Speights presented on Workforce Planning & Development. She presented on the Patient Care Apprenticeship (PCA) and how expanding our relationship with Dallas College helped expand from 45 to 90 apprentice offers in the past year. Next, she presented on the Internal Operations Apprenticeship. She also shared the Workforce Development Programs available. Next, she provided a 2024 timeline review of or org-wide development initiatives. Lastly, she provided an update on Leadership and Professional Development.

The Committee members asked questions and received additional information related to the Patient Care Internal Operations Apprenticeship.

D. Key Metrics

Dan Enright presented on Key Metrics. He noted every metric improved across the board in Q1 2024.

The Committee members asked questions and received additional information related to Key Metrics.

VI. Adjourn

With no further business to discuss, Committee Chair Lisa Sutter adjourned the meeting at 12:48 p.m.

SO RECORDED:

Lisa Sutter Committee Chair	Steve Roth, JD, MPH Assistant Secretary

Minutes 2024-02-07 Governance, Compliance and Ethics Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Minutes of the Governance, Compliance and Ethics Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, February 7, 2024, scheduled for 10:30 a.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Reina Gonzalez, JD, noted that a quorum was physically present and called the meeting to order at 10:33 a.m. Committee members); and Lisa Sutter attended in-person. Committee member Eric G. Bing, MD, PhD attended via Webex. Board member Vincent Hall was appointed for quorum.

Committee members Byron Cryer, MD and Ramon Miguez, PE, did not attend.

Board Member Attendees Included: Chair Marjorie Petty, JD (via Webex).

Staff Present (via Webex and in-person) included:

Donna Richardson, EVP Chief Nursing Executive
Edmundo Castañeda, EVP & Chief Operating Officer
Felicia Miller, EVP & Chief Talent Officer
Forrest Stovall, Governance Program Manager
Fred Cerise, President & Chief Executive Officer
Gerry Baker, SVP Revenue Cycle (in-person)
Jennifer Wimberly, Staff Physician-Chair, Institutional Ethics Committee
Kellee Boardingham, Executive Assistant
Melanie Roberts, SVP/Chief Compliance & Ethics Officer
Rick Humphrey, EVP Chief Financial Officer
Roberto de la Cruz, EVP & Chief Clinical Officer (via Webex)
Roshan Thayil, Sr. Director Compliance Programs
Saul Cordero, SVP Chief Governance & Strategy Officer (via Webex)
Steve Roth, EVP & Chief Legal Officer
Vic Summers, SVP Chief Audit Executive
Compliance and Ethics Department (via Webex)

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval

A. Recognition & Discussion with Compliance & Ethics Department Staff
Melanie Roberts introduced the Compliance & Ethics Department Staff

B. Policies and Procedures
   I. SYS.LEAD.009 Event Reporting to the BOM
   II. SYS.LEG.005 Authorization to Settle Liability Claims

Melanie Roberts presented the Policies and Procedures for approval noting the material changes to each.

Vincent Hall motioned to recommend Board approval of the Policies and Procedures. Lisa Sutter seconded the motion. The motion passed unanimously.

C. Discuss Board Reimbursement Process
Committee Chair presented proposed changes to the Board reimbursement process for discussion. The Board decided on Parkland arranging and pre-paying for Board members airfare, hotel and conference fees while members will still be responsible for submitting receipts for per diem food and incidental reimbursement. Fred Cerise noted that the changes will be put into a policy and brought to the full Board for approval.

Lisa Sutter motioned to recommend Board approval of the proposed changes to the Board Reimbursement Process. Vincent Hall seconded the motion. The motion passed unanimously.

VI. Executive Session

At 10:57 a.m., the Committee went into executive session to discuss the items on the Executive Session agenda.

Members of management were excused from the discussion of topics as necessary.

A. Institutional Ethics Committee Report

B. Compliance and Ethics Report
   I. Annual Compliance Program Review
   II. Electronic Health Record Monitoring
   III. Regulatory Update

C. Quarterly Report of Open Compliance Reviews
Attorney-Client Privileged & Confidential

Members of management in executive session attendance included:

Donna Richardson, Edmundo Castañeda; Felicia Miller; Forrest Stovall; Fred Cerise; Gerry Baker; Jennifer Wimberly; Jessica Hernandez; Kellee Boardingham; Melanie Roberts; Rick Humphrey, Roberto de la Cruz; Roshan Thayil; Saul Cordero; Steve Roth; and Vic Summers

Committee Chair Reina Gonzalez, JD, adjourned Executive Session and moved into Open Session at 11:43 a.m.

Vincent Hall, motioned to recommend Board approval of the allowance of a grace period of six months for the Compliance & Ethics Department to provide other options for an independent third-party to perform external review of the compliance. Lisa Sutter seconded the motion. The motion passed unanimously.

VII. Executive Session

At 11:45 a.m., the Committee went into executive session to discuss the items on the Executive Session agenda.

Members of management were excused from the discussion of topics as necessary.

D. Chief Compliance & Ethics Officer One-on-One with Committee

Committee Chair Reina Gonzalez, JD, adjourned Executive Session and moved into Open Session at 11:56 a.m.

VIII. Adjourn

With no further business to discuss, Committee Chair Reina Gonzalez, JD, adjourned the meeting at 11:57 a.m.

SO RECORDED:

Reina Gonzalez, JD Committee Chair	Steve Roth, JD, MPH Assistant Secretary

Minutes 2024-02-27 Budget & Finance Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Budget and Finance
February 27, 2024

Minutes of the Budget and Finance Committee meeting of the Board of Managers of the Dallas County Hospital District, held Tuesday, February 27, 2024, scheduled for 11:30 a.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Ramon Miguez, PE, noted that a quorum was physically present and called the meeting to order at 11:32 a.m. Committee members Byron Cryer, MD; and Eric G. Bing, MD, PhD attended in-person. Committee member Lisa Sutter attended via Webex. Board member Elizabeth Palacios, MD, was appointed for quorum prior to Dr. Cryer's arrival.

Committee member John Proctor; did not attend.

Board Member attendees included: Chair Marjorie Petty, JD; and Vincent Hall.

Staff Present (via Webex and in-person) included:

April Audain, VP UT Contracts Administration
Donna Richardson, EVP & Chief Nursing Executive
Edmundo Castañeda, EVP Chief Operating Officer
Felicia Miller, EVP & Chief Talent Officer
Forrest Stovall, Governance Program Manager
Fred Cerise, President & Chief Executive Officer
Guy Toliver, Director Inclusion-Supplier Diversity
Jessica Hernandez, SVP Chief DEI Officer
Joe Mayer, Director Treasury
Joseph Longo, SVP Chief Information Officer
Kellee Boardingham, Executive Assistant
Keri Disney-Story, VP Clinical Finance (Webex)
Melanie Roberts, SVP Chief Compliance & Ethics Officer
Pam Bryant, SVP Chief Supply Chain Officer
Rick Humphrey, EVP & Chief Financial Officer (Webex)
Roberto de la Cruz, EVP & Chief Clinical Officer
Saul Cordero, SVP & Chief Governance & Strategy Officer
Steven Roth, EVP & Chief Legal Officer
Vic Summers, SVP Internal Audit

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Approve Contracts over $200,000

Pam Bryant reviewed the briefing documents for contracts over $200,000. (See Appendix A of these minutes for more specific details on each contract.) Discussion of non-sole source contracts was first. Pam Bryant provided a brief overview of each contract and highlighted the MWBE participation.

Next, Pam presented the sole source contracts. She provided a brief overview of each contract and highlighted the MWBE participation.

The Committee asked questions and received further information related to Contracts over $200,000.

Byron Cryer, MD, motioned to recommend Board approval of Contracts over $200,000. Eric G. Bing, MD, PhD seconded the motion. The motion passed unanimously.

B. Approve Capital Substitutions

April Audain presented three capital substitutions for approval. The Capital Substitutions total $376,567.

The Committee asked questions and received additional information related to Capital Substitutions.

John Proctor motioned to recommend Board approval of Capital Substitutions. Eric G. Bing, MD, PhD, seconded the motion. The motion passed unanimously.

C. Parkland Financial Performance Presentation

Rick Humphrey reviewed the financial results for January 2024 and discussed significant performance variances.

For the month of January, Parkland Health recognized a net income of $12.6M which is $6.5M favorable to the budgeted net income of $6.1M and $16.1M favorable compared to the prior year net loss of ($3.5M).

Parkland Health's operating margin and operating cash flow margin for the month of January are 2.2% and 5.4%, respectively. The operating margin was favorable compared to budget of (0.3%) and the operating cash flow margin is also unfavorable compared to budget of 2.9%. Parkland Health's operating margin is favorable compared to the prior

year operating margin of (5.3%) and favorable to the operating cash flow margin of (1.8%) from the prior year.

Parkland Health's patient cash collections in January were $96.1M which is higher than budget by $8.2M and $14.1M above the prior year. Parkland Health's days cash on hand of 204.1 days for the month is an increase of 16.3 days compared to prior month of 187.8 days and compared to the prior year January of 193.7 days, an increase of 10.4 days

Rick Humphrey reviewed the income statement for January 2024. He noted January was positive over all metrics and $6.5 million variance to budget in Total Net Income. He also noted variances to budget including Salaries and Benefits, Purchased Medical Services, and Supplies, Grants and Contributions as well as Nonoperating Income. Next, Rick reviewed the income statement for January 2024 including all Parkland entities.

The Committee asked questions and received further information related to the Income Statements.

Next, Rick reviewed the Key Statistics for the month of January. Hospital Discharges and Average Daily Census had positive variances to budget. He also noted a strong Case Mix.

The Committee asked questions and received further information related to the Key Statistics.

A. **Adjourn**

With no further business to discuss, Committee Chair Ramon Miguez, PE, adjourned the meeting at 12:53 p.m.

SO RECORDED:

Ramon Miguez, PE Committee Chair	Steven Roth, JD, MPH Assistant Secretary

Appendix A (Contracts Reviewed for Approval)

Item	Page No.	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
													February 28, 2024
NON-SOLE SOURCE CONTRACTS - Sorted by Size													
N1		Capital	Annie's Place Learning Center Interior Improvements	The Whiting-Turner Contracting Company	Last Signature - 11/1/2024	$1,878,535	$1,878,535	MATOC	Yes	Paul Woodard, Parkland Design & Construction	23.6%	See chart	See chart
N2		Capital	Psych Intake Expansion	Falkenberg Construction Co., Inc.	Last Signature - 2/28/2025	$614,027	$614,027	Invitation for Bids	Yes	Mark Stewart, Parkland Design and Construction	36.40%	See chart	See chart
N3		Capital	ASC Physical Therapy Renovation	Azteca Enterprises, Inc.	Last Signature - 11/1/2024	$489,155	$489,155	MATOC	Yes	Laura Adair, Parkland Design and Construction	78.60%	See chart	See chart
N4		Capital	Pi Drive Drills	Stryker Sales, LLC, Instrument Division	Last Signature - 5/1/2024	$429,868	$429,868	GPO Purchase	Yes	Cheston Chan, Perioperative Services	0%	N/A	N/A

Appendix A (Continued)

Item	Page No.	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
SOLE SOURCE CONTRACTS - Sorted by Size													
S1		Expense	Mod to Add Funds Add funding for COVID/Flu Testing Kits	Cepheid	3/9/2023 - 3/8/2024	$1,399,000	$2,899,000	Sole Source Modification	Yes	Kristi Morgan/Tim Lenz, Microbiology/Pathology	N/A	N/A	N/A
S2		Expense	Fleet Vehicle Maintenance for standard vehicles, maintenance vehicles, and police vehicles	Planet Ford Dallas Love Field	Last Signature - 3/1/2029	$875,000	$875,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Pamela Bryant, Finance Administration	0%	N/A	N/A
S3		Expense	Mod to Add Funds ROTEM delta System Consumables and Service Contract	Werfen USA, LLC	2/8/2023 - 2/12/2028	$833,500	$903,500	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Gene Fedorko/Tim Lenz, Hematology	0%	N/A	N/A
S4		Expense	Scrub Dispensing Stations Lease and Maintenance	Innovative Product Achievements, LLC	3/1/2024 - 2/28/2029	$815,340	$815,340	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Jay Dyck , Linen Services	0%	N/A	N/A
S5		Expense	Mod #5 Nutrition services	The American Bottling Company	1/17/2017 - 2/28/2025	$729,000	$1,163,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Jeffrey Madison, Nutrition Services	0%	N/A	N/A
S6		Expense	Provider Credentialing Software – Payer Enrollment	QGenda, LLC	Last Signature - No Expiration	$520,000	$520,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Jessica Isokariari / Gerry Baker, PFS Operations	0%	N/A	N/A
S7		Expense	ProCare Service	Stryker	3/1/2024 - 2/28/2027	$450,263	$450,263	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Strategy, Perioperative Services Administration	0%	N/A	N/A
S8		Expense	Epic Boost – Justin Hansmeyer	Epic	2/28/2024 - 10/25/2024	$316,200	$316,200	Sole Source	Yes	Deborah Johnson / LeMar Oleson, Information Technology	0%	N/A	N/A
S9		Capital	PureSteel™ Healthcare Reprocessing Sinks and Accessories	Pure Processing, LLC.	Last Signature - 3/8/2025	$234,261	$234,261	Sole Source	Yes	Cheston Chan, Perioperative Services	0%	N/A	N/A
S10		Expense	Mod #3 Endoscopic GI	Steris Corporation	3/1/2019 - 2/28/2025	$200,000	$800,000	Sole Source	Yes, for the current	Cheston Chan,	0%	N/A	N/A

Appendix A (Continued)

Item	Page No.	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
S11		Expense	Mod #4 Orthopedic Implants	Wright Medical	7/1/2014 - 9/30/2024	$160,000	$816,500	Sole Source Modification	Yes	Cheston Chan, Perioperative Admin	0%	N/A	N/A
S12		Expense	Mod to Add Funds Reagents (A1C kit)	Sysmex America Inc	9/20/2016 - 4/23/2025	$144,000	$869,836	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Gene Fedorko/Tim Lenz, Hematology	0%	N/A	N/A
S13		Capital	Mod #1 Purchase an additional 4 Prismax Systems, Renal Replacement Therapy	Vantive US Healthcare LLC fka Baxter Healthcare Corporation	4/7/2023 - 6/30/2024	$121,360	$455,100	Sole Source Modification	Yes	Marcus Cooper, Clinical Engineering	0%	N/A	N/A

Minutes 2024-02-28 Quality of Care & Patient Safety Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Quality of Care and Patient Safety
February 28, 2024

Minutes of the Quality of Care and Patient Safety Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, February 28, 2024, scheduled for 10:00 a.m. in the WISH Building Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Elizabeth Palacios, MD, noted that a quorum was physically present and called the meeting to order at 10:00 am. Committee members Eric G. Bing, MD, PhD; Byron Cryer, MD; Todd Furniss, JD; and Farida Minner, RN, attended in-person.

Board Member attendees included: Board Chair Marjorie Petty, JD (arrived at 10:14 am); Reina Gonzalez, JD (arrived at 10:34 am); Vincent Hall (arrived at 10:14am); and Ramon Miguez, PE.

Staff Present (via Webex and in-person) included:
Anita Hedge, MD, General Internal Medicine (via Webex)
Brett Moran, ACMO-CMIO (via Webex)
Catharine Chen, MD, UTSW Associate Professor (via Webex)
David Alexander, SVP Nursing
Dawn Marchetto, SVP Nursing
Donna Richardson, EVP & Chief Nursing Executive
Edmundo Castañeda, EVP & Chief Operating Officer
Edward Best, MD, Obstetrics and Gynecology (via Webex)
Felicia Miller, EVP & Chief Talent Officer
Forrest Stovall, Governance Program Manager
Gretchen Blake, VP Quality & Clinical Effectiveness
James Griffin, President of the Medical Executive Committee
Jessica Hernandez, SVP Chief DEI Officer
JD Buchert, MSN, M.Ed., MS, RN
Judy Herrington, SVP Nursing
Karen Garvey, VP Safety & Clinical Risk Management
Kellee Boardingham, Executive Assistant
Madhuri Sopirala, UTSW Associate Professor (via Webex)
Margaret Palmer, VP Professional Medical Affairs (via Webex)
Morgan Simmons, Governance Program Coordinator
Roberto de la Cruz, EVP Chief Clinical Officer
Rosechelle Ruggiero, MD, Associate Professor (via Webex)
Saul Cordero, SVP & Chief Governance & Strategy Officer
Sobha Fuller, SVP Nursing
Shauntee Mayfield, VP, Chief Experience Officer (via Webex)
Steven Roth, EVP Chief Legal Officer

Parkland

MINUTES
Dallas County Hospital District Board of Managers

Quality of Care and Patient Safety
February 28, 2024

II. Mission Statement

Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Executive Session – Quality & Patient Safety Operations Section

At 10:00 a.m. the Committee moved into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics as necessary.

Members of management in executive session attendance included:

David Alexander, Dawn Marchetto, Donna Richardson, Edmundo Castañeda, Felicia Miller, Forrest Stovall, Gretchen Blake, James Griffin, Jessica Hernandez, Judy Herrington, Karen Garvey, Kellee Boardingham, Madhuri Sopirala, Margaret Palmer, Morgan Simmons, Roberto de la Cruz, Saul Cordero, Sobha Fuller, and Steven Roth.

In executive session, the Committee received the presentation and reports as specified in the posted agenda.

A. Chief Quality & Safety Officer Report: Executive Quality Committee (EQC) Summary
   Dr. de la Cruz gave this summary as Dr. Lane was absent for the day

B. Patient Safety & Clinical Risk
   1. Cause Analysis (CA) Case Reviews and Guide
   2. Workplace Violence Update (Biannual)

C. Clinical Quality Reports
   1. Department Performance Improvement Committee (PIC)/ Clinical Quality Committee (CQC) Annual Presentation
      a. Respiratory PIC
   2. Patient Satisfaction: HCAHPS

The Committee reviewed all items on the agenda, asked questions and received additional information.

VI. Executive Session Reference Documents

A. Executive Summaries
B. Quality of Care dashboard
C. Quality of Care Report
D. Cause Analysis (CA) Log
E. Supplemental Cause Analysis
F. Workplace Violence Supplemental Information
G. Department Performance Improvement Committee (PIC): Nutrition PIC Report
H. Contracts Oversight Committee Biannual Update

VII. Executive Session: Medical Executive Committee ("MEC")

James D. Griffin, MD, President of the Medical Executive Committee, discussed the items posted on the agenda starting at 11:37am.

A. Appointments/Reappointments
    1. Medical Staff & Non-Physician Clinical Providers to Parkland Health
        a. Credentialing Report
        b. Delineation of Privileges (DoPs)
            i. Cardiovascular and Thoracic DoP

The Board asked questions and received additional information.

Members of management in the MEC executive session attendance included:

Donna Richardson, Edmundo Castañeda, Felicia Miller, Forrest Stovall, James Griffin, Jessica Hernandez, Kellee Boardingham, Margaret Palmer, Morgan Simmons, Roberto de la Cruz, Saul Cordero, and Steven Roth.

VIII. Executive Session: Chief Quality & Safety Officer (CQSO) One-on-One with Committee

The Committee did not conduct a One-on-One with the CQSO, Dr. Mike Lane.

IX. Executive Session: Medical Executive Committee President One-on-One with Committee

The Committee did not conduct a One-on-One with the Medical Executive Committee President, Dr. James Griffin.

Chair adjourned Executive Session and moved into Open Session at 12:07 pm.

X. Action Items (Open Session)

A. Approve Medical Executive Committee Recommendations
1. Approval of the Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers
    a. Credentialing Report
    b. Delineation of Privileges (DoPs)
        i. Cardiovascular and Thoracic DoP

Byron Cryer, MD, motioned to recommend Board approval of the Medical Executive Committee Recommendations. Eric G. Bing, MD, PhD, seconded the motion. The motion passed unanimously.

XI. Follow-Up Requests: None

XII. Closing Remarks

XIII. Adjourn

With no further business to discuss, Committee Chair Elizabeth Palacios, MD, adjourned the meeting at 12:08 pm.

SO RECORDED:

Elizabeth Palacios, MD Committee Chair	Steven Roth, JD, MPH Assistant Secretary

Minutes 2024-02-28 Board of Managers

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Minutes of the Board of Managers meeting of the Dallas County Hospital District, held Wednesday, February 28, 2024, scheduled for 12:50 p.m. (or immediately following the HOMES meeting) in the WISH Building Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Chair Marjorie Petty, JD, noted that a quorum was physically present and called the meeting to order at 12:57 p.m.

Board Member attendees included: Chair Marjorie Petty, JD; Eric G. Bing, MD, PhD; Byron Cryer, MD; Todd Furniss, JD; Vincent Hall; Ramon Miguez, PE; Farida Minner, RN; Reina Gonzalez, JD; Elizabeth Palacios, MD; and Lisa Sutter.

John Proctor did not attend.

Staff Present (via Webex and in-person) included:
Bruce McDaniels, VP & Chief Information Security Officer
Donna Richardson, EVP & Chief Nursing Executive
Edmundo Castañeda, EVP & Chief Operating Officer
Felicia Miller, EVP & Chief Talent Officer
Forrest Stovall, Governance Program Manager
Fred Cerise, President & Chief Executive Officer
Jessica Hernandez, SVP Chief DEI Officer
Joe Longo, SVP/Chief Information Officer
John Riggi, National Advisor for Cybersecurity and Risk (AHA)
Kellee Boardingham, Executive Assistant
Melanie Roberts, SVP Chief Compliance & Ethics Officer
Morgan Simmons, Governance Program Coordinator
Pam Bryant, SVP Chief Supply Chain Officer
Rick Humphrey, EVP & Chief Financial Officer (Webex)
Saul Cordero, SVP Chief Governance & Strategy Officer
Steven Roth, EVP & Chief Legal Officer
Vic Summers, SVP Chief Audit Executive

Other Attendees
Brooklin Miller
Tzeggabrhan Kidane

II. Mission Statement

The Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Invocation

Reverend Myron Hardy of The Omni Church offered an invocation at the beginning of the meeting.

IV. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

V. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

VI. Consent Agenda

Minutes 2024-01-17 Facilities Committee

Minutes 2024-01-23 Audit Committee

Minutes 2024-01-23 Budget & Finance Committee

Minutes 2024-01-24 Quality of Care & Patient Safety Committee

Minutes 2024-01-24 Board of Managers

Approve Contracts over $200,000

Approve Capital Substitution(s)

Approve Prescriptive Authority Delegation for Advanced Practice Registered Nurses and Physician Assistants, SYS.MS.002

Approve Investment Policy-Defined Benefit Plan, 8311-1-14

Approve Authorization to Settle Liability Claims, SYS.LEG.005

Approve Event Reporting to the Board of Managers, SYS.LEAD.009

Approve General Victim Assistance Grant

Approve Extension of External Review of Compliance Program

Approve Patient Settlements

Approve Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

Chair requested Item I. Approve Investment Policy-Defined Benefit Plan, 8311-1-14 and Item M. Approve Extension of External Review of Compliance Program be excluded for further discussion.

Todd Furniss, JD motioned to approve the Consent Agenda with the exception of Item I. Approve Investment Policy-Defined Benefit Plan, 8311-1-14 and Item M. Approve Extension of External Review of Compliance Program. Ramon Miguez, PE, seconded the motion. The motion passed unanimously.

Chair stated that Item I. Approve Investment Policy-Defined Benefit Plan, 8311-1-14 doesn't list the full Board on page 89 as needing to avoid conflict of interest and votes to have the policy amended with the addition of that language. The Board also received additional information on the Extension of External Review of Compliance Program.

Todd Furniss, JD, motioned to approve Item I. Approve Investment Policy-Defined Benefit Plan, 8311-1-14 with language adding the full board to page 89. Vincent Hall seconded the motion. The motion passed unanimously.

Reina Gonzalez, JD, motioned to approve Item M. Approve Extension of External Review of Compliance Program. Lisa Sutter seconded the motion. The motion passed unanimously.

VII. Reports Requiring Deliberation(s) or Approval(s)

A. CEO Update on System Operations

Dr. Fred Cerise announced nurse award season and Donna Richardson commented on the D Magazine and Great 100 nursing awards.

B. Questions & Discussion Related to CEO Update on System Operations

The Board asked questions and received additional information related to the CEO Update on System Operations

VIII. Executive Session

At 1:29 p.m., the Board went into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics as necessary.

A. Cybersecurity Update

B. Questions & Discussion Related to Cybersecurity

C. Consultation with Attorney Regarding Parkland Center for Clinical Innovation (PCCI) and Pieces Technology, Inc (PTI) Agreement

D. Discussion Regarding Roles and Responsibilities of the Board of Managers in the Governance and Strategic Direction of the System

E. Personnel Matters Pertaining to Duties and Responsibilities of Chief Executive Officer

F. Personnel Matters Pertaining to Duties and Responsibilities of Board Members

Members of management in executive session attendance included:

Bruce McDaniels, Donna Richardson, Edmundo Castañeda, Felicia Miller, Forrest Stovall, Fred Cerise, Joe Longo, Kellee Boardingham, Jessica Hernandez, Melanie Roberts, Morgan Simmons, Rick Humphrey, Saul Cordero, Steven Roth, and Vic Summers

Chair adjourned Executive Session and moved into Open Session at 4:30 p.m.

IX. Action items (Open Session)

A. Amended Retained Rights Agreement and PCCI Asset Purchase Agreement Resolution
Todd Furniss, JD, motioned to approve the Amended Retained Rights Agreement and PCCI Asset Purchase Agreement Resolution. Vincent Hall, seconded the motion. The motion passed unanimously.

X. Adjourn

With no further business to discuss, the Chair adjourned the meeting at 4:33 p.m.

SO RECORDED:

Marjorie D. Petty, JD Chair	Steven Roth, JD, MPH Assistant Secretary

Approve Parkland Center for Clinical Innovation (PCCI) Board Re-appointments

About PCCI Board

The PCCI Board recommends a slate of two appointments to the PCCI Board for terms beginning in 2024: Dr. Paula Dobbs-Wiggins for a three-year term and Bob Smith for a three-year term.

About PCCI Board

PCCI currently has a seven-member Board of Directors consisting of:

Mandatory Members:

- Marge Petty, Chair of the Parkland Board of Managers
- Fred Cerise, M.D., Parkland CEO
- Steve Miff, PCCI CEO

Five Appointed members:

- Ted Shaw (immediate past President, THA and interim executive at Parkland)
- Bob Smith (health care consultant and interim executive at Parkland)
- Wilfred Parnell, M.D. (former Chair of Parkland Board)
- Dick Daniels (retired CIO of Kaiser Permanente)
- Paula Dobbs-Wiggins, M.D. (former Chair of Parkland Board)

Recommended Appointments

- Dr. Dobbs-Wiggins served on the PCCI Board in her prior role as Chair of the Parkland Board of Managers and has been serving on the PCCI Board in an appointed capacity since 2022. The PCCI Board recommends Dr. Dobbs-Wiggins for a three-year term based on her deep knowledge of mental-behavioral health issues which are critical to supporting PCCI's focus on Social Determinants of Health.

- Bob Smith is the longest-serving PCCI Board member and a former interim executive for Parkland. The PCCI Board recommends Mr. Smith's re-appointment for his fourth three-year term because his "institutional memory" and service as the Chair of the PCCI Finance/Audit/Compliance Committee has been and is expected to continue to be invaluable to the company.

Approve Contracts over $200,000

Full Board - Contracts for Approval

Item	Page No.	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
													March 27, 2024
					NON-SOLE SOURCE CONTRACTS - Sorted by Size								
N1		Capital	Construction Manager at Risk (CMAR) for Vickery Clinic	Russell + Post L Joint Venture	4/1/2024 - 9/30/2025	$22,551,400	$22,551,400	Request for Proposals (Best Value)	Yes	Laura Adair, Parkland Design and Construction	30%	TBA	TBA
N2		Expense	Mod #6 Extension of Third-Party Administration for Retirement Benefit Plan.	Milliman Inc.	4/1/2013 - 9/30/2025	$1,726,671	$25,411,871	Non-Sole Source Modification	Yes	Tawana McCullough, Office of Talent Management	0%	N/A	N/A
N3		Expense	Mod #5 Level III armed guard service for new security screening services	Vets Securing America	1/1/2022 - 12/31/2024	$1,114,156	$2,432,738	Non-Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Marlin Suell, Police Department	0%	N/A	N/A
N4		Expense	Operational Reports	Prominence Advisors, LLC	3/27/2024 - 3/26/2027	$990,000	$990,000	Request for Proposals (Low Price/Tech Accept)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Adam Taufique, Information Technologies	0%	N/A	N/A
N5		Capital	Behavior Health Beds	Sizewise Rentals, LLC	Last Signature - 4/3/2025	$215,784	$215,784	GPO Purchase	Yes	Patrick Eaton, Clinical Engineering	0%	N/A	N/A

Full Board - Contracts for Approval

Item	Page No.	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
SOLE SOURCE CONTRACTS - Sorted by Size													
S1		Expense	New 3-year agreement for Cepheid COVID, respiratory, and non-respiratory assays testing	Cepheid	4/1/2024 - 3/31/2027	$5,800,000	$5,800,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristi Morgan/Tim Lenz, Microbiology/Pathology	0%	N/A	N/A
S2		Expense	Mod #5 SAP Analytics & Digital Boardroom License	SAP	11/19/2020 - No Expiration	$2,906,904	$3,492,531	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Adam Taufique / James Gaston, Information Technology	0%	N/A	N/A
S3		Expense	Mod #4 Endoprosthesis Vascular Stents and Implants	W. L. Gore & Associates, Inc.	5/1/2021 - 4/30/2026	$2,613,000	$7,206,000	Sole Source Modification	Yes, for the current fiscal year. Additional years' costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan and John Camacho, Operating Room and Interventional Radiology	0%	N/A	N/A
S4		Expense	Mod #5 Craniomaxillofacial (CMF) Implants	Stryker Sales, LLC.	11/1/2020 - 12/31/2025	$1,349,000	$2,998,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Operating Room	0%	N/A	N/A
S5		Expense	Trauma Implants and Accessories	OsteoCentric Technologies, Inc	4/1/2024 - 3/31/2027	$1,187,000	$1,187,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
S6		Expense	Orthopedic and Trauma Supplies	Acumed	4/1/2024 - 3/31/2028	$646,400	$646,400	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
S7		Expense	Wound vac rentals for hospital-at-home patients	KCI USA, Inc	5 days after Last Signature - 4 years	$401,576	$401,576	Sole Source	Yes	Alissa Tran, Hospital at Home	0%	N/A	N/A
S8		Expense	Genetic Testing Laboratory Services funding	Foundation Medicine Inc	3/28/2024 - 3/27/2025	$350,000	$350,000	Sole Source	Yes	Scott Hampton/ Fidel Ramirez, Laboratory Services	0%	N/A	N/A
S9		Expense	Mod #3 Endoflip Capital and Disposables	Covidien Sales LLC	Last Signature - 12/31/2024	$304,568	$494,568	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Gastroenterology Lab	0%	N/A	N/A

Full Board - Contracts for Approval

Item	Page No.	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
S10		Expense	Mod #4 Blanketrol III and EnsoETM Purchase Agreement	Advanced Cooling Therapy Inc.	8/6/2021 - 8/5/2026	$300,001	$500,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Electrophysiology Lab	0%	N/A	N/A
S11		Expense	Mod to Add Funds Neuro Interventional Products	Medtronic USA, Inc.	10/24/2018 - 10/31/2024	$285,000	$1,713,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
S12		Expense	Ellipsys Capital Equipment and Disposable Products	Medtronic	Last Signature - 3 Years	$270,000	$270,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
S13		Expense	Genetic Testing Laboratory Services funding	Genomic Health Inc	3/28/2024 - 3/27/2025	$250,000	$250,000	Sole Source	Yes	Scott Hampton/ Fidel Ramirez, Laboratory Services	0%	N/A	N/A
S14		Expense	Mod to Add Funds WavelinQ Catheters	Bard Peripheral Vascular, Inc.	4/4/2020 - 2/26/2025	$143,000	$339,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
S15		Expense	Mod to Add Funds Venaseal & ClosureFast Products	Medtronic USA, Inc.	12/24/2019 - 12/23/2024	$54,000	$253,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
DEVIATION/RATIFICATION													
D1		Expense-Approved Deviation	FDA Remediation Plan and Fleet Refresh	CareFusion Solutions, LLC	3/15/2024 - 12/31/2024	$1,662,912	$1,662,912	GPO Purchase	No, CAP contingency funds and substitution	Donna Richardson, Nursing Administration	0%	N/A	N/A

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Construction Manager at Risk (CMAR) for Vickery Clinic	
Business Owner: Laura Adair	**Business Owner Dept:** Parkland Design and Construction	**Contract Number:** POCRE-23703
Vendor/Supplier/Contractor: Russell + Post L Joint Venture	**Source Selection Methodology:** Request for Proposals (Best Value)	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	4/1/2024 – 9/30/2025	$22,551,400
Out Years:	0 Year(s)	+$0
Total:	4/1/2024 – 9/30/2025	$22,551,400

Lowest Bidder

Is this contractor the lowest bidder/supplier? No
If not, what premium will be paid for this contract over the lowest bidder? $1,070,741

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? Yes; and Construction is approved

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: This award is to a M/WBE vendor.
Were M/WBE's Directly Solicited? Yes
Number Responding M/WBE's: 2
What % of this contract is M/WBE? 30%
M/WBE Race/Ethnicity? TBD
M/WBE Gender? TBD

Submitted By (Division VP): John Raish, Senior Vice President, Support Services

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Construction Manager at Risk (CMAR) for Vickery Clinic

VENDOR: Russell + Post L Joint Venture

COST:

Base Term:	$22,551,400
Out Years:	+ $0
Total:	$22,551,400

Recommendation
Approve this contract for Construction Manager at Risk (CMAR) for Vickery Clinic.

Background
This contract is for the hiring of a Construction Manager at Risk (CMAR) for the Vickery Clinic project. A CMAR will perform preconstruction services and administer the construction work on behalf of the District and is required to competitively award all of the construction work through subcontracts. The total build-out is approximately 30,000 square feet at a projected total project cost of $31,337,800. The CMAR will competitively award all of the construction work through bid packages creating a Guaranteed Maximum Price (GMP) for the project. Pre-Construction services, General Conditions and bonding valued at $2,429,000 is included in the total.

Fair and Reasonable Price Determination
A fair and reasonable price was determined through adequate competition. The costs have been reviewed by the Facilities team and a Fair and Reasonable price was determined through historical pricing for similar construction projects and the District's internal estimates. Based on Parkland's internal knowledge and assessment of the costs, the costs are in line with the market.

Competitive Range				
Vendor	**Key Strengths**	**Key Weaknesses**	**Non-Cost Score Max. 300pts**	**Price Differential**
Russell + Post L JV	Project overseer was instrumental in prior Parkland project.		273	$1,070,741
Vendor B	Prior Parkland experience	Preconstruction fee, bonding capacity	272	$102,838
Vendor C	Provided two separate schedules for flexibility and reduced cost	Team roles not clearly defined. Missing information.	268	$86,555
Vendor D	Experience working with project architectural firm	Limited experience for JV partner	268	$0
Vendor E	Strong team with multiple projects with JV	No team profile, no work schedule	267	$121,548
Vendor F	Quality Assurance Plan	Only three full time team members for project. No Estimator listed	266	$76,133

Vendor G	Solid healthcare experience	Experience of key personnel is limited, evidence of ability to perform is weak	254	$67,337
Vendor H	Integrated team structured approach with Parkland	Team not complete at time of submittal. Schedule missing detail	248	$277,311
Vendor I	Understanding of ADA compliance requirements	No org chart, no info for Factor 3. Healthcare experience weak	219	$191,501

Financial Forecast

Base Term	FY2024
Expenses	$22,551,400

Document Contact/Author:	Steve Adrian

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 6 Extension of Third-Party Administration for Retirement Benefit Plan.	
Business Owner: Tawana McCullough	**Business Owner Dept:** Office of Talent Management	**Contract Number:** HR-19574_A4
Vendor/Supplier: Milliman Inc. **Basis of Original Contract Award** Request for Proposals (Best Value) **Basis of this Modification** Non-Sole Source Modification	BOM Approved Contract Total (8/22/2019):	$23,685,200
Revenue, Expense or Capital: Expense	Modification # 6 Amount:	$1,726,671
Original Start Date: 4/1/2013 **Current Expiration:** 9/30/2024 **Mod Start Date:** 10/1/2024 **Expiration after this Mod:** 9/30/2025	New Contract Amount:	$25,411,871

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Felicia Miller, Executive Vice President & Chief Talent Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH & HOSPITAL SYSTEM
BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 6 Extension of Third-Party Administration for Retirement Benefit Plan.

VENDOR: Milliman Inc.

COST:

BOM Approved Contract Total (8/22/2019):	$23,685,200
Modification # 6:	+ $1,726,671
Total:	$25,411,871

Recommendation
Approve this contract modification to Extension of Third-Party Administration for Retirement Benefit Plan..

Background
Milliman is Parkland's current Third-Party Administrator (TPA) for the Parkland Retirement Plans. Parkland has made significant changes with the pension and savings plans that were effective January 1,2024. The current TPA's familiarity with Parkland will enable them to assist during the first year of the new MSP and closing the Pension Plan to new participants. This contract will go for RFP in 2025.

Fair and Reasonable Price Determination
A fair and reasonable price was determined through adequate competition.

Financial Forecast

Current Contract Amount	FY2025	Total
$23,685,200	$1,726,671	$25,411,871

Document Contact/Author:	Terence Durham

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 5 Level III armed guard service for new security screening services	
Business Owner: Marlin Suell	**Business Owner Dept:** Police Department	**Contract Number:** PONCS-20399 A6
Vendor/Supplier: Vets Securing America **Basis of Original Contract Award** Request for Proposals (Best Value) **Basis of this Modification** Non-Sole Source Modification	BOM Approved Contract Total (6/28/2023)	$1,318,582
Revenue, Expense or Capital: Expense	Modification # 5 Amount:	$1,114,156
Original Start Date: 1/1/2022 **Current Expiration:** 12/31/2023 **Mod Start Date:** Upon Execution **Expiration after this Mod:** 12/31/2024	New Contract Amount:	$2,432,738

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): John Raish, Senior Vice President, Support Services

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 5 Level III armed guard service for new security screening services

VENDOR: Vets Securing America

COST:

BOM Approved Contract Total (6/28/2023)	$1,318,582
Modification # 5:	+ $1,114,156
Total:	$2,432,738

Recommendation
Approve this contract modification to Level III armed guard service for new security screening services.

Background
This contract is for level III armed guard services due to the purchase of eighteen (18) additional Passive Security Screening/Weapons Detection units. Implementation of the new units will require an increase of armed security personnel services currently being provided by VSA for oversight of the screening stations.

Fair and Reasonable Price Determination
A fair and reasonable price was originally determined through adequate competition.

Financial Forecast

Current Contract Amount	FY2024	FY2025	Total
$1,318,582	$557,078	$557,078	$2,432,738

Document Contact/Author:	Elizabeth Addleman

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Operational Reports	
Business Owner: Adam Taufique	**Business Owner Dept:** Information Technologies	**Contract Number:** POIT-23930
Vendor/Supplier/Contractor: Prominence Advisors, LLC	**Source Selection Methodology:** Request for Proposals (Low Price/Tech Accept)	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	3/27/2024 – 3/26/2027	$990,000
Out Years:	0 Year(s)	+$0
Total:	3/27/2024 – 3/26/2027	$990,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? Yes
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? Yes; and IT approved
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, but supplier diversity received their corporate plan.
Were M/WBE's Directly Solicited? Yes
Number Responding M/WBE's: 0
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Joe Longo, Senior Vice President & Chief Information Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Operational Reports

VENDOR: Prominence Advisors, LLC

COST:		
	Base Term:	$990,000
	Out Years:	+ $0
	Total:	$990,000

Recommendation
Approve this contract for Operational Reports.

Background
This contract is to secure resources for Enterprise Data Services (EDS) to perform report and dashboard development. This service is needed to alleviate our significant backlogged work queue of outstanding requests. This model worked during covid so we are confident it will be the best way to address the current volume issue.

Fair and Reasonable Price Determination

A fair and reasonable price was determined through adequate competition.

Competitive Range				
Vendor	**Key Strengths**	**Key Weaknesses**	**Non-Cost Score**	**Price Differential**
Prominence Advisors, LLC	Strong EPIC background, clear process and governance, proven reduction of duplicate reports.		95.75	
Vendor B	Well established, strong track record, seasoned officers	Examples lack solid experience; most examples reflect database rather than reporting	76	$5,928,072

Financial Forecast

Base Term	FY2024	FY2025	FY2026	Totals
Services	$330,000	$330,000	$330,000	$990,000

Document Contact/Author:	Farrah Smith

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Behavior Health Beds	
Business Owner: Patrick Eaton	**Business Owner Dept:** Clinical Engineering	**Contract Number:** POCP-23939
Vendor/Supplier/Contractor: Sizewise Rentals, LLC	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	Last Signature – 4/3/2025	$215,784
Out Years:	0 Year(s)	+$0
Total:	Last Signature – 4/3/2025	$215,784

Lowest Bidder

Is this contractor the lowest bidder/supplier? GPO Purchase

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? 0%

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): John Raish, Senior Vice President, Support Services

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Behavior Health Beds

VENDOR: Sizewise Rentals, LLC

COST:		
	Base Term:	$215,784
	Out Years:	+ $0
	Total:	$215,784

Recommendation
Approve this contract for Behavior Health Beds.

Background
This contract is for replacements for 40 behavior health beds for Correctional Health. There are 80 beds currently at the jail that are past End of Support and parts to repair are no longer available. This will allow us to replace half with the remaining beds planned for replacement in FY25.

Fair and Reasonable Price Determination
The GPO contract and pricing was obtained in a solicitation process performed by Vizient. Market research conducted through ECRI shows that Parkland price is 18.7% lower than the average for other facilities. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2024
Equipment / Licenses	$215,784

Document Contact/Author:	Andrew Barter

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** New 3-year agreement for Cepheid COVID, respiratory, and non-respiratory assays testing	
Business Owner: Kristi Morgan/Tim Lenz	**Business Owner Dept:** Microbiology/Pathology	**Contract Number:** POCP-23913
Vendor/Supplier/Contractor: Cepheid	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Historical Pricing

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	4/1/2024 – 3/31/2027	$5,800,000
Out Years:	0 Year(s)	+$0
Total:	4/1/2024 – 3/31/2027	$5,800,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? 0%

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): Vivian Johnson, Senior Vice President, Clinical Services

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: New 3-year agreement for Cepheid COVID, respiratory, and non-respiratory assays testing

VENDOR: Cepheid

COST:		
	Base Term:	$5,800,000
	Out Years:	+ $0
	Total:	$5,800,000

Recommendation
Approve this contract for new 3-year agreement for Cepheid COVID, respiratory, and non-respiratory assays testing.

Background
This contract is for reagents for assays testing with our Cepheid equipment. The Cepheid equipment is used for COVID, respiratory, and non-respiratory testing within our Microbiology department. Parkland owns the Cepheid equipment, and these reagents are proprietary to the system. This is to update and replace existing reagent contract for the next three years.

Fair and Reasonable Price Determination
Market research conducted through ECRI shows that Parkland's price is average in comparison to other facilities. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2024	FY2025	FY2026	FY2027	Totals
Expenses / Consumables	$1,127,778	$1,933,333	$1,933,334	$805,555	$5,800,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. Limitations are imposed on the products/services by proprietary restrictions. The reagents are proprietary to the Parkland owned equipment.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 5 SAP Analytics & Digital Boardroom License	
Business Owner: Adam Taufique / James Gaston	**Business Owner Dept:** Information Technology	**Contract Number:** POIT-18762 A5
Vendor/Supplier: SAP **Basis of Original Contract Award** Sole Source **Basis of this Modification** Non-Sole Source Modification	BOM Approved Contract Total (11/17/2020):	$585,627
	Modifications Totaling < $100,000 Modification # 1 - 4 Amount: (Maintenance and Support)	$2,108,069
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 5 Amount:	$798,835
Original Start Date: 11/19/2020 **Current Expiration:** No Expiration **Mod Start Date:** 3/27/2024 **Expiration after this Mod:** No Expiration	New Contract Amount:	$3,492,531

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	Yes; and IT approved
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Joe Longo, Senior Vice President & Chief Information Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 5 SAP Analytics & Digital Boardroom License

VENDOR: SAP

COST:

BOM Approved Contract Total (11/17/2020):	$585,627
Modification # 1 - 4	$2,108,069
Modification # 5:	+ $798,835
Total:	$3,492,531

Recommendation

Approve this contract modification to SAP Analytics & Digital Boardroom License.

Background

This contract is to purchase an additional 1,000 licenses to allow users to login to our Business Objects portal to run clinical reports. Parkland currently has 1,000 licenses with a current total of around 1,700 who need to log in, which leaves 700 users unable to login to the portal. This purchase will bring our total to 2,000 for Enterprise Data Services and other leadership who run reports on a daily, weekly, monthly basis.

Fair and Reasonable Price Determination

This is an expansion of our current licensing at a similar rate as previously paid during the initial procurement and follow-on expansions that has been further discounted by a global/promotion incentive.

Financial Forecast

Current Contract Amount	FY2021	FY2023	FY2024	FY2025	FY2026	Total
$585,627	$30,450	$2,077,619	$123,835	$300,000	$375,000	$3,492,531

Sole Source Justification

This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount. This is an expansion of our existing infrastructure.

Document Contact/Author:	Tonya Calhoun

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 4 Endoprosthesis Vascular Stents and Implants	
Business Owner: Cheston Chan and John Camacho	**Business Owner Dept:** Operating Room and Interventional Radiology	**Contract Number:** POCP-19370 A4
Vendor/Supplier: W. L. Gore & Associates, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (3/29/2023):	$4,593,000
Revenue, Expense or Capital: Expense	Modification # 4 Amount:	$2,613,000
Original Start Date: 5/1/2021 **Current Expiration:** 4/30/2024 **Mod Start Date:** 5/1/2024 **Expiration after this Mod:** 4/30/2026	New Contract Amount:	$7,206,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years' costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, SVP Nursing, Executive Nursing Leadership

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 4 Endoprosthesis Vascular Stents and Implants

VENDOR: W. L. Gore & Associates, Inc.

COST:

BOM Approved Contract Total (3/29/2023):	$4,593,000
Modification # 4:	+ $2,613,000
Total:	$7,206,000

Recommendation
Approve this contract modification to Endoprosthesis Vascular Stents and Implants.

Background
This contract is for the procurement of Vascular Stents and Implants. These products are used in the Operating Room, Cardiac Cath Lab, and Interventional Radiology for improving blood flow in patients with symptomatic peripheral arterial disease.

Fair and Reasonable Price Determination
Market research conducted through ECRI shows that Parkland's price is in line with the national market average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2024	FY2025	FY2026	Total
$4,593,000	$544,375	$1,306,500	$762,125	$7,206,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	William Jones

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 5 Craniomaxillofacial (CMF) Implants	
Business Owner: Cheston Chan	**Business Owner Dept:** Operating Room	**Contract Number:** POCP-18469 A5
Vendor/Supplier: Stryker Sales, LLC. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (1/25/2023):	$1,649,000
	Modifications Totaling < $100,000 Modification # 4 Amount:	$99,000
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification # 5 Amount:	$1,250,000
Original Start Date: 11/1/2020 **Current Expiration:** 3/31/2024 **Mod Start Date:** 4/1/2024 **Expiration after this Mod:** 12/31/2025	New Contract Amount:	$2,998,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 5 Craniomaxillofacial (CMF) Implants

VENDOR: Stryker Sales, LLC.

COST:

BOM Approved Contract Total (1/25/2023):	$1,649,000
Modification # 4:	$99,000
Modification # 5:	+ $1,250,000
Total:	$2,998,000

Recommendation
Approve this contract modification for Craniomaxillofacial (CMF) Implants.

Background
This contract is to purchase Craniomaxillofacial and Neuro Fixation implants used by the Surgical Team.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 25% less than median pricing. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2024	FY2025	FY2026	Total
$1,649,000	$385,429	$770,857	$192,714	$2,998,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	Bryson Hendrix

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Trauma Implants and Accessories	
Business Owner: Cheston Chan	**Business Owner Dept:** Perioperative Services	**Contract Number:** POCP-24125
Vendor/Supplier/Contractor: OsteoCentric Technologies, Inc	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	4/1/2024 – 3/31/2027	$1,187,000
Out Years:	0 Year(s)	+$0
Total:	4/1/2024 – 3/31/2027	$1,187,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? 0%

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Trauma Implants and Accessories

VENDOR: OsteoCentric Technologies, Inc

COST:		
	Base Term:	$1,187,000
	Out Years:	+ $0
	Total:	$1,187,000

Recommendation
Approve this contract for Trauma Implants and Accessories.

Background
This contract is to purchase trauma implants and accessories used in orthopedic surgery to stabilize and repair broken bones.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is average as compared to other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2024	FY2025	FY2026	FY2027	Totals
Expenses / Consumables	$197,833	$395,666	$395,666	$197,835	$1,187,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	Ashley Meister

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Orthopedic and Trauma Supplies	
Business Owner: Cheston Chan	**Business Owner Dept:** Perioperative Services	**Contract Number:** POCP-23857
Vendor/Supplier/Contractor: Acumed	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	4/1/2024 – 3/31/2026	$323,200
Out Years:	2 Year(s)	+$323,200
Total:	4/1/2024 – 3/31/2028	$646,400

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? 0%

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): David Alexander, SVP Nursing, Executive Nursing Leadership

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Orthopedic and Trauma Supplies

VENDOR: Acumed

COST:		
	Base Term:	$323,200
	Out Years:	+ $323,200
	Total:	$646,400

Recommendation
Approve this contract for Orthopedic and Trauma Supplies.

Background
This contract is for the Surgery areas for orthopedic and trauma supplies. These are specialty orthopedic implants used for shoulder surgery.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is average as compared to other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	**FY2024**	**FY2025**	**FY2026**	**FY2027**	**FY2028**	**Totals**
Expenses / Consumables	$80,800	$161,600	$80,800			$323,200
Out Years	**FY2024**	**FY2025**	**FY2026**	**FY2027**	**FY2028**	**Totals**
Expenses / Consumables			$80,800	$161,600	$80,800	$323,200
Totals	$80,800	$161,600	$161,600	$161,600	$80,800	$646,400

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	Ashley Meister

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Wound vac rentals for hospital-at-home patients	
Business Owner: Alissa Tran	**Business Owner Dept:** Hospital at Home	**Contract Number:** POCP-22085
Vendor/Supplier/Contractor: KCI USA, Inc	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** District Internal Estimates

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	5 days after Last Signature – 4 years	$401,576
Out Years:	0 Year(s)	+0
Total:	5 days after Last Signature – 4 years	$401,576

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: N/A-no solicitation performed
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Roberto de la Cruz, Executive Vice President, Chief Clinical Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Wound vac rentals for hospital-at-home patients

VENDOR: KCI USA, Inc

COST:		
	Base Term:	$401,576
	Out Years:	+ 0
	Total:	$401,576

Recommendation
Approve this contract for Wound vac rentals for hospital-at-home patients.

Background
This contract is for wound vac rentals for our hospital-at-home patients. The wound vac (vacuum assisted closure) is a therapeutic technique using a suction pump, tubing and a dressing to remove excess fluid from a wound and promote healing in acute and chronic wounds,

Fair and Reasonable Price Determination
Benchmarking was completed thru ECRI and they not able to provide recent benchmarking data for rentals. Parkland wound vac subject matter experts internally estimated the daily rental rate to be fair and reasonable.

Financial Forecast

Base Term	FY2024	FY2025	FY2026	FY2027	Totals
Expenses / Consumables	$58,078	$88,395	$114,594	$140,509	$401,576

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount.

Document Contact/Author:	Stephanie Toth

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Genetic Testing Laboratory Services funding	
Business Owner: Scott Hampton/ Fidel Ramirez	**Business Owner Dept:** Laboratory Services	**Contract Number:** PO #10213
Vendor/Supplier/Contractor: Foundation Medicine Inc	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Prices Established by Law or Regulation

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	3/28/2024 – 3/27/2025	$350,000
Out Years:	0 Year(s)	+$0
Total:	3/28/2024 – 3/27/2025	$350,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: N/A-no solicitation performed
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Vivian Johnson, Senior Vice President, Clinical Services

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Genetic Testing Laboratory Services funding

VENDOR: Foundation Medicine Inc

COST:		
	Base Term:	$350,000
	Out Years:	+ $0
	Total:	$350,000

Recommendation
Approve this contract for Genetic Testing Laboratory Services funding .

Background
Foundation Medicine provides genetic testing services. They provide FDA approved testing of predictive and prognostic tumor markers in the treatment of various cancers using both blood and tissue specimens.

Fair and Reasonable Price Determination
Benchmarking research was conducted through ECRI and they were unable to provide price recommendations. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2024	FY2025	FY2026	Totals
Expenses / Consumables	$102,083	$175,000	$72,917	$350,000

Sole Source Justification
FoundationOne Liquid CDx is the only FDA-approved blood-based test to analyze over 300 genes, making it the most comprehensive FDA-approved liquid biopsy on the Market. This contract is for a service for which there is only one acceptable source. The product or service has no competition.

Document Contact/Author:	Tamisha Smallwood

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 3 Endoflip Capital and Disposables	
Business Owner: Cheston Chan	**Business Owner Dept:** Gastroenterology Lab	**Contract Number:** POCP-19267 A3
Vendor/Supplier: Covidien Sales LLC **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Contract Amount:	$190,000
Revenue, Expense or Capital: Expense	Modification # 3 Amount:	$304,568
Original Start Date: 10/15/2021 **Current Expiration:** 12/31/2024 **Mod Start Date:** Last Signature **Expiration after this Mod:** 12/31/2024	New Contract Amount:	$494,568

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 3 Endoflip Capital and Disposables

VENDOR: Covidien Sales LLC

COST:		
	Current Contract Amount:	$190,000
	Modification # 3:	+ $304,568
	Total:	$494,568

Recommendation
Approve this contract modification to Endoflip Capital and Disposables.

Background
This contract is for the purchase of equipment and disposable used with the equipment. The Endoflip system is indicated for use in a clinical setting to measure pressure and dimensions in the esophagus, pylorus, (opening from the stomach to the small intestines), and anal sphincters(muscles). It is used as a supplement as part of a comprehensive evaluation of patients with symptoms consistent with gastrointestinal motility disorders. This capital equipment is required to adhere to guidelines Parkland uses for confirmatory diagnosis using Endoclip and now part of the new Chicago Classification 4.0 guidelines that Parkland uses for manometry and any esophagogastric junction outflow obstruction must have confirmatory diagnosis using Endoflip.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is average as compared to other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2024	FY2025	FY2026	Total
$190,000	$88,832	$152,283	$63,453	$494,568

Sole Source Justification
VA research through Lumere shows the Endoflip System from Medtronic is the only system that utilizes impedance manometry as the measurement technique compared to other similar systems to meet Parkland needs. This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount.

Document Contact/Author:	Bryson Hendrix

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod # 4 Blanketrol III and EnsoETM Purchase Agreement	
Business Owner: Cheston Chan	**Business Owner Dept:** Electrophysiology Lab	**Contract Number:** POCP-19891
Vendor/Supplier: Advanced Cooling Therapy Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Contract Amount:	$199,999
Revenue, Expense or Capital: Expense	Modification # 4 Amount:	$300,001
Original Start Date: 8/6/2021 **Current Expiration:** 8/5/2024 **Mod Start Date:** 8/6/2024 **Expiration after this Mod:** 8/5/2026	New Contract Amount:	$500,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 4 Blanketrol III and EnsoETM Purchase Agreement

VENDOR: Advanced Cooling Therapy Inc.

COST:		
	Current Contract Amount:	$199,999
	Modification # 4:	+ $300,001
	Total:	$500,000

Recommendation
Approve this contract modification to Blanketrol III and EnsoETM Purchase Agreement.

Background
The Blanketrol III System and ensoETM disposables are used in the Electrophysiology Lab and is designed to reduce, maintain, or elevate a patient's temperature. The ensoETM is a single-use tube inserted into the esophagus and connected to the Blanketrol III. Water circulates inside the closed loop system to efficiently cool or warm through the esophagus.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is average as compared to other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2024	FY2025	FY2026	Total
$199,999	$25,000	$150,000	$125,001	$500,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The product or service has no competition. Confirmed by the Electrophysiology Lab and Value Analysis.

Document Contact/Author:	Bryson Hendrix

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod to Add Funds Neuro Interventional Products	
Business Owner: John Camacho	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-19594 A5
Vendor/Supplier: Medtronic USA, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (2/22/2023):	$1,428,000
	Modifications Totaling < $100,000 Modification # 6 Amount:	$99,000
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Modification to Add Funds Amount:	$186,000
Original Start Date: 10/24/2018 **Current Expiration:** 10/31/2024 **Mod Start Date:** 3/27/2024 **Expiration after this Mod:** 10/31/2024	New Contract Amount:	$1,713,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Legal approved base document, amendment has no changes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Vivian Johnson, Senior Vice President, Clinical Services

Parkland

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod to Add Funds Neuro Interventional Products

VENDOR: Medtronic USA, Inc.

COST:

BOM Approved Contract Total (2/22/2023):	$1,428,000
Modification # 6:	$99,000
Modification to Add Funds:	+ $186,000
Total:	$1,713,000

Recommendation

Approve this contract modification for Neuro Interventional Products.

Background

This contract is for the purchase of Neuro Interventional products. Medtronic coils and accessories are used in the treatment of acute stroke patients in Interventional Radiology procedures. Medtronic systems are used to remove blood clots and control bleeding in the brain for patients whose clinical pathology and anatomy match the design strengths of these products.

Fair and Reasonable Price Determination

Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 3% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2023	FY2024	FY2025	Total
$1,428,000	$99,000	$108,500	$77,500	$1,713,000

Sole Source Justification

This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	William Jones

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Ellipsys Capital Equipment and Disposable Products	
Business Owner: Cheston Chan	**Business Owner Dept:** Perioperative Services	**Contract Number:** POCP-23861
Vendor/Supplier/Contractor: Medtronic	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	Last Signature – 3 Years	$270,000
Out Years:	0 Year(s)	+$0
Total:	Last Signature – 3 Years	$270,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? 0%

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Ellipsys Capital Equipment and Disposable Products

VENDOR: Medtronic

COST:		
	Base Term:	$270,000
	Out Years:	+ $0
	Total:	$270,000

Recommendation
Approve this contract for Ellipsys Capital Equipment and Disposable Products.

Background
This contract is for the purchase of equipment and disposables for vascular surgery. The equipment provides a minimally invasive option for patients with an irregular connection between an artery and a vein known as Arteriovenous Fistula. This allows patients with kidney disease to receive dialysis treatment.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 5% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2024	FY2025	FY2026	FY2027	Totals
Expenses / Consumables	$60,000	$90,000	$90,000	$30,000	$270,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The product or service has no competition.

Document Contact/Author:	Bryson Hendrix

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: March 27, 2024	**Product or Service:** Genetic Testing Laboratory Services funding	
Business Owner: Scott Hampton/ Fidel Ramirez	**Business Owner Dept:** Laboratory Services	**Contract Number:** PO #9900
Vendor/Supplier/Contractor: Genomic Health Inc	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Prices Established by Law or Regulation

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	3/28/2024 – 3/27/2025	$250,000
Out Years:	0 Year(s)	+$0
Total:	3/28/2024 – 3/27/2025	$250,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: N/A-no solicitation performed
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Vivian Johnson, Senior Vice President, Clinical Services

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Genetic Testing Laboratory Services funding

VENDOR: Genomic Health Inc

COST:		
	Base Term:	$250,000
	Out Years:	+ $0
	Total:	$250,000

Recommendation
Approve this contract for Genetic Testing Laboratory Services funding.

Background
This contract is to purchase specific genetic testing services. Genomic Health has developed a proprietary-genomic assay that quantifies the likelihood of breast cancer recurrence. This is used by the pathology department.

Fair and Reasonable Price Determination
Pricing has historically remained the same since Parkland has been using these testing services. Parkland has been using these services for two years now.

Financial Forecast

Base Term	FY2024	FY2025	FY2026	Totals
Expenses / Consumables	$72,917	$125,000	$52,083	$250,000

Sole Source Justification
Genomic Health has developed a proprietary-genomic assay that quantifies the likelihood of breast cancer recurrence. This contract is for a service for which there is only one acceptable source. The product or service has no competition.

Document Contact/Author:	Tamisha Smallwood

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod to Add Funds WavelinQ Catheters	
Business Owner: John Camacho	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-21024 A3
Vendor/Supplier: Bard Peripheral Vascular, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Contract Amount:	$196,000
Revenue, Expense or Capital: Expense	Mod to Add Funds Amount:	$143,000
Original Start Date: 4/4/2020 **Current Expiration:** 2/26/2025 **Mod Start Date:** 3/27/2024 **Expiration after this Mod:** 2/26/2025	New Contract Amount:	$339,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Legal approved base document, amendment has no changes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Vivian Johnson, Senior Vice President, Clinical Services

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod to Add Funds WavelinQ Catheters

VENDOR: Bard Peripheral Vascular, Inc.

COST:		
	Current Contract Amount:	$196,000
	Modification to Add Funds:	+ $143,000
	Total:	$339,000

Recommendation
Approve this contract modification to WavelinQ Catheters.

Background
WavelinQ percutaneous arteriovenous fistula (AVF) catheters are used with the WavelinQ EndoAVF generator to create an endovascular AV fistula for hemodialysis access in patients with chronic kidney disease who need dialysis. The catheters use a completely endovascular approach in vessels that are not traditionally used during open surgery. It is necessary to add funding at this time due to usage in excess of original estimates.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price aligns with other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2024	FY2025	Total
$196,000	$83,417	$59,583	$339,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount.

Document Contact/Author:	William Jones

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: March 27, 2024	**Modification:** Mod to Add Funds Venaseal & ClosureFast Products	
Business Owner: John Camacho	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-22172 A3
Vendor/Supplier: Medtronic USA, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Contract Amount:	$199,000
Revenue, Expense or Capital: Expense	Mod to Add Funds Amount:	$54,000
Original Start Date: 12/24/2019 **Current Expiration:** 12/23/2024 **Mod Start Date:** 3/27/2024 **Expiration after this Mod:** 12/23/2024	New Contract Amount:	$253,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Vivian Johnson, Senior Vice President, Clinical Services

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # Venaseal & ClosureFast Products

VENDOR: Medtronic USA, Inc.

COST:		
	Current Contract Amount:	$199,000
	Modification # :	+ $54,000
	Total:	$253,000

Recommendation
Approve this contract modification to Venaseal & ClosureFast Products.

Background
This contract is to purchase Venaseal & ClosureFast endovenous radiofrequency ablation (RFA) catheters. They are used with the ClosureFast radiofrequency generator to collapse and close enlarged leg veins in patients with varicose veins and Chronic Venous Insufficiency (CVI) in Interventional Radiology procedures. The disposables allow for minimally invasive thermal treatment. It is necessary to add funding at this time due to usage in excess of original estimates.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 12% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2024	FY2025	Total
$199,000	$31,500	$22,500	$253,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount.

Document Contact/Author:	William Jones

Parkland

Approved Deviation Request
New Contract

Must be approved before: March 15, 2024	**Reason for deviation request**: CareFusion Solutions (BD) announced its final FDA remediation plan and has an enhanced value of $6.6M through a total fleet replacement if we sign our remediation plan by March 15th.

BOM Date: April 24,2024	**Product or Service:** FDA Remediation Plan and Fleet Refresh	
Business Owner: Donna Richardson	**Business Owner Dept:** Nursing Administration	**Contract Number:** POCP-24176
Vendor/Supplier/Contractor: CareFusion Solutions, LLC	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Expense-Approved Deviation

	Contract Dates	Contract Price
Base Term:	3/15/2024 – 12/31/2024	$1,662,912
Out Years:	0 Year(s)	+$0
Total:	3/15/2024 – 12/31/2024	$1,662,912

Lowest Bidder

Is this contractor the lowest bidder/supplier?	GPO Purchase
If not, what premium will be paid for this contract over the lowest bidder?	N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency?	Yes
Does this contract have an IT Component?	Yes; and IT approved
Does this contract have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	No, CAP contingency funds and substitution
FTE Impact:	None

Diversity

Potential for M/WBE engagement:	Vendor self performs; there are no opportunities through subcontractors, but supplier diversity received their corporate plan.
Were M/WBE's Directly Solicited?	N/A-no solicitation performed
Number Responding M/WBE's:	N/A-no solicitation performed
What % of this contract is M/WBE?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Pam Bryant, Senior Vice President, Chief Supply Chain Officer

Request: Authorize the appropriate Contracting Officer to execute this contract with the stipulation that it will be presented to the Parkland Board of Managers for approval at the next regularly scheduled meeting.

Fred Cerise
Fred Cerise (Mar 13, 2024 19:21 CDT)

Dr. Fred Cerise, President & CEO **Date:** Mar 13, 2024

RFMA
RFMA (Mar 14, 2024 13:04 CDT)

Chair Finance Committee **Date:** Mar 14, 2024

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH & HOSPITAL SYSTEM
BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: FDA Remediation Plan and Fleet Refresh

VENDOR: CareFusion Solutions, LLC

COST:

Base Term:	$1,662,912
Out Years:	+ $0
Total:	$1,662,912

Recommendation
Approve this contract for FDA Remediation Plan and Fleet Refresh.

Approved Deviation Reason
Parkland Health will need to sign the FDA remediation plan and fleet refresh by March 15th to receive an additional benefit from CareFusion to receive all new devices meeting all FDA requirements instead of repairing existing devices that are less than 7 years old as required by the FDA. This is advantageous to Parkland because as part of the FDA 510(k) approval for IV pumps, the FDA have established a mandatory 10-year use life which means that remediated devices would still have a finite end of life in 2029. By receiving all new devices, Parkland would effectively be extending the useful life of its entire fleet to 2034, an additional 5 years for no additional cost, a cost avoidance of $6.63M in value.

Background
Parkland refreshed its entire fleet of pumps in March of 2019 and Carefusion Solutions announced a recall of their devices for various reasons in 2020. As part of that remediation Carefusion Solutions had to refile for final 510(K) approvals and agree to provide certain upgrades to devices less than 7 years old. CareFusion solutions is required to remediate and update all the devices that were less than 7 years old. However, this left 801 devices within the Parkland fleet that were in excess of 10 years old that must be replaced, including all syringe/PCA pumps in order to continue support of patients in the NICU and requiring self-administered pain management. Parkland will not be responsible for vendor payment until all devices have been replaced as part of the remediation plan. This may not occur until October 2024, which would place the funding in FY25.

Fair and Reasonable Price Determination
The GPO contract and pricing was obtained in a solicitation process performed by Vizient. Market research conducted through ECRI shows that Parkland price is consistent for other facilities. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2024
Equipment	$1,662,912

Document Contact/Author:	Michelle Duffey

Approve Capital Substitution(s)

Parkland Health
2024 Capital Substitution
For March 2024 Board Meeting

Ref #	Division	Project Total	Substitution Amount	Description
1	Supply Chain	$1,662,912	$1,662,912	**Infusion Pump Fleet Replacement**
	Explanation	A large portion of the existing infusion pump fleet (801 out of 4,097 pumps) is over 7 years old and requires replacement to comply with the remediation plan as multiple FDA vulnerabilities and alerts have been identified with Parkland's infusion pump fleet. The Parkland Contracts Dept has negotiated a complete fleet replacement and we will receive 4,097 pumps at the cost of 801 pumps (which is a savings of $6.6M).		
	Driver(s) of Increased Expense:	Cybersecurity vulnerabilities caused the increased expense. Cybersecurity vulnerabilities could allow an "attacker" to use the pumps as an entry point to Parkland's network and gain access to other networked systems. They would also be able to run remote code to the pumps to take them offline or control them.		
	Description of Item:	Infusion pump: An infusion pump continuously or intermittently delivers fluids, medications, blood and blood products to adult, pediatric, or neonatal patients.		
Grand Total		**$1,662,912**	**$1,662,912**	

PARKLAND HEALTH

RESOLUTION NO. _____

Be it resolved, the Parkland Health Board of Managers, by a vote of _____ Yes and _____ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health management requests approval for the use of contingency funds for capital items in the amount of $1,662,912 for FY23 as itemized in the listing presented to the Board of Managers, and

THEREFORE, BE IT RESOLVED, that the Parkland Health Board of Managers approves the use of funds as submitted.

Dated this ____th Day of _____2024.

_____
Marjorie Petty, JD
Chair

_____
Steven Roth, JD, MPH
Assistant Secretary

Marjorie Petty, JD	Yes_____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes_____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes_____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes_____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes_____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes_____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes_____	No _____	Abstain _____	Absent _____
Ramon Miguez, PE	Yes_____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes_____	No _____	Abstain _____	Absent _____
John Proctor	Yes_____	No _____	Abstain _____	Absent _____

Approve Patient Settlements

Approve Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH

RESOLUTION NO. _____

RESOLUTION

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of _____YES and ____ NAY, does by this resolution (adopt/reject) _____the following:

WHEREAS, the Medical Executive Committee recommends approval of the Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers as presented.

THEREFORE BE IT RESOLVED that the Board of Managers approves the recommended Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers.

Dated this 27th of March, 2024

_____	_____
Marjorie D. Petty, JD	Steve Roth, JD, MPH
Chair	Assistant Secretary

Marjorie D. Petty, JD	Yes_____ No_____ Abstain _____Absent_____
Elizabeth Palacios, MD	Yes_____ No_____ Abstain _____Absent_____
Todd Furniss, JD	Yes_____ No_____ Abstain _____Absent_____
Eric G. Bing, MD, PhD	Yes_____ No_____ Abstain _____Absent_____
Byron Cryer, MD	Yes_____ No_____ Abstain _____Absent_____
Reina Gonzalez, JD	Yes_____ No_____ Abstain _____Absent_____
Vincent Hall	Yes_____ No_____ Abstain _____Absent_____
Ramon Miguez, PE	Yes_____ No_____ Abstain _____Absent_____
Farida Minner, RN	Yes_____ No_____ Abstain _____Absent_____
John Proctor	Yes_____ No_____ Abstain _____Absent_____
Lisa Sutter	Yes_____ No_____ Abstain _____Absent_____

CEO System Update

Questions & Discussion Related to CEO System Update

Parkland Health Foundation Update

Parkland Health Foundation Update

Michael A. Horne
President and CEO, Parkland Health Foundation

March 27, 2024

Parkland Health Foundation Mission

We secure substantial philanthropic investments to enable Parkland Health to advance a national standard of excellence in public healthcare.

Philanthropic Spotlight

Parkland Health Foundation

Neva and Don Cochran

"Parkland is the premier hospital in Dallas delivering state-of-the-art healthcare services from outstanding healthcare providers for people with limited resources. For many, it is the only hospital that will take care of them, yet they receive the benefit of some of the best physicians in the country, either trained or teaching at UTSW. Supporting all the people in Dallas, especially those in underserved areas, makes our entire city and county a stronger and better place to live and work."

-Neva Cochran, Parkland Health Philanthropic Investor

President's Report

Parkland Health Foundation

Philanthropic Priorities

Parkland Health Foundation

Parkland Health Center at Dallas College – Richland Campus

Addressing gaps in patient access to quality preventive health care close to where they reside, work and play

Goal: $12,500,000

Pediatric Behavioral Health

Improving child and adolescent mental health through an integrated approach across Parkland

Goal: $12,500,000

Expanding Family Planning Services

Providing Family Planning services and contraception of choice for women and girls

Goal: $12,500,000

Cancer Care

Providing cancer care to help prevent, detect, and treat cancer

Goal: $7,500,000

FY24 Performance Summary

We continue to see strong fundraising and revenue growth in fiscal year 2024 buoyed by approved Parkland Health projects.

Fundraising As of 3/17/2024



FY24 Fundraising Goal: $10,850,000

Revenue As of 3/8/2024



FY24 Revenue Goal: $11.4 million

Fundraising Priorities Snapshot

Parkland Health Foundation

Fundraising Priorities Snapshot				
FY24 Priority	**Philanthropic Goal**	**FY24 Funds Raised**	**3-Year Funds Raised**	**Remaining**
Cancer Care	$6,500,000	$437,408	$3,484,284	$3,015,716
Family Planning	$12,500,000	$733,500	$2,829,263	$9,670,737
Pediatric Behavioral Health	$12,500,000	$976,295	$9,707,373	$2,792,627
Richland Health Center	$12,500,000	$255,900	$1,760,730	$10,739,270
TOTAL	**$44,000,000**	**$2,403,103**	**$17,781,650**	**$26,218,350**

Crystal Charity Ball Bus Tour

Parkland Health Foundation

Community Engagement

Parkland Health Foundation

HBA DFW Presents

Mental Health Matters: Ways to Enhance and Expand Mental Health Resources

Join us for an enlightening discussion that will address the prevalent mental health challenges impacting our communities. We'll provide a thorough examination of opportunities and strategies to effectively tackle these issues.

Dr. Horne, a prominent figure in healthcare leadership, will share insights on initiatives aimed at enhancing mental health resources. Maribeth Kuenzi, Associate Professor at SMU - Cox School of Business, will join him to provide valuable perspectives on critical issues and actionable improvement strategies.

This fireside chat aims to showcase progress in addressing mental health challenges and highlight unique initiatives shaping mental health support in North Texas. Gain valuable insights into the future of mental health advocacy and the vision for a resilient community.

Don't miss this opportunity to deepen your understanding of mental wellness challenges and opportunities.

Date & time
Tuesday, 27 February
5:30 PM - 8:00 PM CST

Location
SMU - Cox School of Business,
3150 Binkley Avenue,Dallas, TX

Event contact
Sonali Pandhe
dfwhba@gmail.com

Cost
Member $30
Guest $45

Register
https://bit.ly/SMUCox

Event sponsor

SMU Cox School of Business

Featured speakers

Michael Horne
President and CEO, Parkland Health Foundation

Maribeth Kuenzi
Associate Professor, SMU-Cox School of Business

The Dallas Morning News
Date: Monday, February 26, 2024
Location: DALLAS, TX
Circulation (DMA): 132,884 (5)
Type (Frequency): Newspaper (D)
Page: 6A
Section: Main
Keyword: Parkland Health

OPINION

Planned health center shows power of philanthropy

Parkland's outpatient reach grows with commitment to education and community

By MARY McDERMOTT COOK

"Health is more than absence of disease; it is about economics, education, environment, empowerment and community." These are the words from former Surgeon General Joycelyn Elders.

manded good architecture for the buildings for each of the Dallas community colleges around our beloved city.

So for Parkland Health to bring its medical expertise to the Richland campus that she selected further cements the connection among health, education and community.

The Dallas Morning News
Date: Wednesday, February 07, 2024
Location: DALLAS, TX
Circulation (DMA): 132,884 (5)
Type (Frequency): Newspaper (D)
Page: 14A
Section: Main
Keyword: Dallas County Hospital District

Step up to keep students calm, safe and healthy

We can channel pride in region's booming economy to take care of our kids

By MICHAEL HORNE and ABIGAIL WILLIAMS

Walk any elementary school campus and you'll hear it — a

affordable housing, food deserts and the cost of reliable transportation create a disproportionate and compounding challenge before

reverse the trajectory of our city's under-resourced communities, the alarming stats will overtake our pride in Dallas' miracle story of boom-

Health Matters: A Candid Conversation

Parkland Health Foundation will host a panel discussion focused on the family planning barriers women and girls in Dallas County face and the solutions that will expand access to care.

- Thursday, April 25, 2024 // 5:30-7PM
- Moody Outpatient Center at Parkland Health

Parkland
Health Foundation

ParklandHealthFoundation.org

Questions & Discussion Regarding Parkland Health Foundation Update

Artificial Intelligence (AI) Update

Questions & Discussion Regarding Artificial Intelligence (AI) Update

Discuss Board of Managers Annual Operating Plan Meeting and Board Development

Real Estate Purchase Opportunity

Executive Session

Questions & Discussion Regarding Real Estate Purchase Opportunity

Executive Session

Discussion Regarding Roles and Responsibilities of the Board of Managers in the Governance and Strategic Direction of the System

Executive Session

Personnel Matters Pertaining to Duties and Responsibilities of Chief Executive Officer

Personnel Matters Pertaining to Duties and Responsibilities of Board Members

Medical Executive Committee Credentialing Report

Delineation of Privileges Cardiovascular Disease – Laser Privileges

Delineation of Privileges
Non-Physician Clinical Provider Staff – Pediatrics/Neonatology

Patient Settlements